DrugPatentWatch Database Preview➤ Subscribe for complete access
« Back to Dashboard
Nintedanib esylateis the generic ingredient in one branded drug marketed by Boehringer Ingelheim and is included in one NDA. There are five patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.
Nintedanib esylate has two hundred and forty-one patent family members in fifty-one countries.
There are nine drug master file entries for nintedanib esylate. One supplier is listed for this compound. There is one tentative approval for this compound.
Generic filers with tentative approvals for NINTEDANIB ESYLATE
The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.
Pharmacology for nintedanib esylate
|Drug Class||Kinase Inhibitor |
|Mechanism of Action||Protein Kinase Inhibitors |
Anatomical Therapeutic Chemical (ATC) Classes for nintedanib esylate
|Country||Patent Number||Estimated Expiration|
|Montenegro||00353||⤷ Try it Free|
|Malaysia||127956||⤷ Try it Free|
|Serbia||20050046||⤷ Try it Free|
|European Patent Office||2878297||⤷ Try it Free|
|Egypt||24562||⤷ Try it Free|
|Norway||330486||⤷ Try it Free|
|>Country||>Patent Number||>Estimated Expiration|
|Patent Number||Supplementary Protection Certificate||SPC Country||SPC Expiration||SPC Description|
|1830843||132016000021977||Italy||⤷ Try it Free||PRODUCT NAME: NINTEDANIB, SUOI TAUTOMERI, O LORO MISCELE O I SUOI SALI, IN PARTICOLARE ESILATO DI NINTEDANIB(OFEV); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/14/979, 20150119|
|1224170||PA2015015||Lithuania||⤷ Try it Free||PRODUCT NAME: NINTEDANIBUM; REGISTRATION NO/DATE: EU/1/14/954/001-004 20141121|
|1830843||CA 2015 00036||Denmark||⤷ Try it Free||PRODUCT NAME: NINTEDANIB ELLER EN TAUTOMER, BLANDINGERNE DERAF ELLER ET SALT DERAF, SAERLIGT NINTEDANIB ESILAT; REG. NO/DATE: EU/1/14/979/001-004 20150115|
|1830843||C300747||Netherlands||⤷ Try it Free||PRODUCT NAME: NINTEDANIB, OF EEN TAUTOMEER,; REGISTRATION NO/DATE: EU/1/14/979 20150115|
|1224170||C01224170/01||Switzerland||⤷ Try it Free||PRODUCT NAME: NINTEDANIB; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 65330 13.08.2015|
|1830843||92762||Luxembourg||⤷ Try it Free||PRODUCT NAME: NINTEDANIB , OU UN TAUTOMERE, LES MELANGES OBTENUS OU UN DESES SELS, EN PARTICULIER NINTEDANIB ESILATE. FIRST REGISTRATION: 20150119|
|>Patent Number||>Supplementary Protection Certificate||>SPC Country||>SPC Expiration||>SPC Description|
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.